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MaBACKGROUND The improvement in discrimination gained by adding nontraditional cardiovascular risk markers cited in
the 2013 American College of Cardiology/American Heart Association cholesterol guidelines to the atherosclerotic car-
diovascular disease (ASCVD) risk estimator (pooled cohort equation [PCE]) is untested.
OBJECTIVES This study assessed the predictive accuracy and improvement in reclassiﬁcation gained by the addition of
the coronary artery calcium (CAC) score, the ankle–brachial index (ABI), high-sensitivity C-reactive protein (hsCRP) levels,
and family history (FH) of ASCVD to the PCE in participants of MESA (Multi-Ethnic Study of Atherosclerosis).
METHODS The PCE was calibrated (cPCE) and used for this analysis. The Cox proportional hazards survival model,
Harrell’s C statistics, and net reclassiﬁcation improvement analyses were used. ASCVD was deﬁned as myocardial
infarction, coronary heart disease–related death, or fatal or nonfatal stroke.
RESULTS Of 6,814 MESA participants not prescribed statins at baseline, 5,185 had complete data and were included in
this analysis. Their mean age was 61 years; 53.1% were women, 9.8% had diabetes, and 13.6% were current smokers.
After 10 years of follow-up, 320 (6.2%) ASCVD events occurred. CAC score, ABI, and FH were independent predictors of
ASCVD events in the multivariable Cox models. CAC score modestly improved the Harrell’s C statistic (0.74 vs. 0.76;
p ¼ 0.04); ABI, hsCRP levels, and FH produced no improvement in Harrell’s C statistic when added to the cPCE.
CONCLUSIONS CAC score, ABI, and FH were independent predictors of ASCVD events. CAC score modestly
improved the discriminative ability of the cPCE compared with other nontraditional risk markers.
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ABBR EV I A T I ON S
AND ACRONYMS
ABI = ankle–brachial index
ACC = American College of
Cardiology
AHA = American Heart
Association
ASCVD = atherosclerotic
cardiovascular disease
CAC = coronary artery calcium
CHD = coronary heart disease
CI = conﬁdence interval
cPCE = calibrated pooled
cohort equation
CT = computed tomography
DM = diabetes mellitus
FH = family history
hsCRP = high-sensitivity
C-reactive protein
MI = myocardial infarction
NRI = net reclassiﬁcation
improvement
PCE = pooled cohort equation
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140I n the recently published guidelines onassessment of cardiovascular risk andtreatment of blood cholesterol to reduce
atherosclerotic risk in adults (1,2), the
American College of Cardiology (ACC) and
the American Heart Association (AHA) intro-
duced a new risk prediction tool using pooled
cohort equations (PCEs) for primary athero-
sclerotic cardiovascular disease (ASCVD) (1).
The ACC/AHA cholesterol guidelines also
recommend the use of additional markers
to improve ASCVD risk assessment and medi-
cal decision making, especially in individuals
in whom the decision to initiate statins is un-
clear (2). The additional markers mentioned
included low-density lipoprotein cholesterol,
other genetic hyperlipidemias, family history
(FH) of premature ASCVD, high-sensitivity C-
reactive protein (hsCRP) levels, coronary ar-
tery calcium (CAC) score, lifetime ASCVD
risk, and ankle–brachial index (ABI).
The ACC/AHA cholesterol guidelines did
not cite data or provide evidence concerning
what the yield would be when using theserisk markers as additional tests for primary ASCVD
risk assessment (2). To address this gap, the present
report describes the improvement in discrimination
afforded by the addition of the CAC score, hsCRP
levels, ABI, and FH of premature ASCVD, over and
beyond the PCE, for 10-year ASCVD events in
asymptomatic adult participants in MESA (Multi-
Ethnic Study of Atherosclerosis).SEE PAGE 148METHODS
The MESA study design has been published previ-
ously (3). Brieﬂy, MESA is a prospective population-
based cohort study investigating the prevalence,
correlates, and progression of subclinical cardiovas-
cular disease in persons without known cardiovas-
cular disease at baseline. The full cohort includes
6,814 women and men aged 45 to 84 years recruited
from 6 U.S. communities (Baltimore, Maryland;
Chicago, Illinois; Forsyth County, North Carolina; Los
Angeles County, California; northern Manhattan,
New York; and St. Paul, Minnesota). MESA included
38% white, 28% African-American, 22% Hispanic, and
12% Chinese adults. Demographic characteristics,
medical history, and anthropometric and laboratory
data for the present study were gathered from the
ﬁrst examination (July 2000 to August 2002). The
MESA study was approved by the institutional reviewboards of each study site, and written informed con-
sent was obtained from all participants.
For the present analysis, participants were
excluded who had missing data related to traditional
or additional risk factors or to follow-up; also
excluded were those who were using statins at base-
line. Our analyses were restricted to participants age
40 to 75 years because they were identiﬁed in the
guidelines as having the strongest data indicating a
beneﬁt from statin therapy for primary prevention.
CONVENTIONAL RISK FACTORS. As part of the
baseline examination, clinical teams collected infor-
mation on traditional and additional putative car-
diovascular risk factors. Current smoking was deﬁned
as having smoked a cigarette in the past 30 days.
Medication use was based on medication inventory.
Diabetes mellitus (DM) was deﬁned as self-reported
history of diabetes, use of diabetes medication, or a
fasting glucose level $126 mg/dl. Resting blood
pressure was measured 3 times in the seated position,
with the average of the second and third readings
recorded. Hypertension was deﬁned as a systolic
blood pressure $140 mm Hg, diastolic blood
pressure $90 mm Hg, or use of antihypertensive
medication. Body mass index was calculated as
weight (in kilograms) divided by height (in meters
squared). Total and high-density lipoprotein choles-
terol were measured from blood samples obtained
after a 12-h fast; low-density lipoprotein cholesterol
was estimated by using the Friedewald equation (4).
ADDITIONAL GUIDELINE-RECOMMENDED RISK MARKERS.
Determining the presence of genetic hyperlipidemias,
as recommended in the guidelines (2), was not
assessed in the present analysis because this infor-
mation was not collected in MESA. Also, we did not
assess lifetime ASCVD risk because it can only be
calculated in adults age 20 to 59 years, and many
MESA participants are age >59 years. In addition, to
create the lifetime risk calculator, only cohorts with
>15 years of follow-up were included, which is
beyond the duration of follow-up in MESA.
FH OF ASCVD. In MESA, we did not speciﬁcally
deﬁne FH of ASCVD as premature (i.e., before the age
of 55 years for men and 65 years for women). Instead,
such a history was obtained by asking participants
whether any member in their immediate family
(ﬁrst-degree relatives [parents, siblings, or children])
had experienced a fatal or nonfatal myocardial
infarction (MI) or stroke. Age at onset of the event
was not speciﬁed, and it is therefore unknown
whether the events were premature.
LEVELS OF hsCRP. The levels of hsCRP were
measured by using the BNII nephelometer (N High
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141Sensitivity CRP, Dade Behring, Inc., Deerﬁeld, Illi-
nois) at the Laboratory for Clinical Biochemistry
Research (University of Vermont, Burlington, Ver-
mont). Analytical intra-assay coefﬁcients of variation
ranged from 2.3% to 4.4%, and interassay coefﬁcients
of variation ranged from 2.1% to 5.7%, with a detec-
tion level of 0.18 mg/l.
CAC SCORE. Details of the MESA computed tomog-
raphy (CT) scanning and interpretation methods
have been reported by Carr et al. (5). Scanning cen-
ters assessed CAC by using chest CT scans with
either a cardiac-gated electron-beam CT scanner
(Chicago, Los Angeles, and New York ﬁeld centers) or
a multidetector CT system (Baltimore, Forsyth
County, and St. Paul ﬁeld centers). Certiﬁed tech-
nologists scanned all participants twice over phan-
toms of known physical calcium concentration.
A radiologist or cardiologist read all CT scans at a
central reading center (Los Angeles Biomedical
Research Institute at Harbor–UCLA, Torrance,
California). The mean Agatston score was used for
the 2 scans in all analyses (6). Intraobserver and
interobserver agreements were excellent (k ¼ 0.93
and k ¼ 0.90, respectively).
ANKLE–BRACHIAL INDEX. Details of the MESA ABI
measurement protocol have been published by Criqui
et al. (7). Brieﬂy, systolic blood pressure measure-
ments in the bilateral brachial, dorsalis pedis, and
posterior tibial arteries were obtained in the supine
position by using a hand-held Doppler instrumentwith
a 5-mHz probe. To avoid potential bias from subclavian
stenosis, the higher of the brachial artery pressures
was used as the denominator. For each lower extrem-
ity, the ABI numerator used was the highest pressure
(dorsalis pedis or posterior tibial) from that leg.
Reproducibility of the ABI was evaluated by using
measurements of 43 participants by 2 technicians. The
inter-reader and intrareader correlation coefﬁcients
were 0.845 and0.937, respectively,with an intrareader
and inter-reader coefﬁcient of variation of 5.14% and
3.27%. Participants with an ABI $ 1.4 were excluded.
EVENT ASCERTAINMENT. A detailed description of
the event ascertainment procedures and the adjudi-
cation process in MESA has been published (8).
Brieﬂy, every 9 to 12 months since the baseline ex-
amination, MESA participants (or, when necessary,
their proxies) are contacted to inquire about hospital
admissions, diagnosis of cardiovascular disease, and
death that may have occurred. Hospital and other
documentation of possible cardiovascular events and
deaths are subsequently obtained. These documen-
tations are sent to at least 2 MESA morbidity and
mortality committee members for adjudicationusing a standard protocol. This committee included
cardiologists, physician epidemiologists, and neurol-
ogists. All possible events with disagreements after
adjudication by at least 2 MESA morbidity and mor-
tality members were discussed and voted on by the
committee during their monthly meetings. For the
purposes of this study, incident ASCVD was deﬁned
as adjudicated MI, coronary heart disease (CHD)-
related death, and fatal and nonfatal stroke as
described by the MESA protocol.
STATISTICAL ANALYSIS. Baseline characteristics are
presented as mean  SD for continuous variables and
percentages for categorical variables. Analyses were
performed to address 2 speciﬁc questions, as dis-
cussed in the following text.
1 . Are the add i t iona l r i sk markers independent
pred ic tors of ASCVD events? Additional markers
were treated as continuous variables (with the
exception of FH). Normalizing log transformation was
used for hsCRP and CACþ1. Cox proportional hazards
analysis was used to assess the association between
each of the markers (CAC score, ABI, hsCRP levels,
and FH) and incident ASCVD in univariable and
multivariable models adjusting for age, sex, race/
ethnicity, total and high-density lipoprotein choles-
terol, DM, cigarette use, body mass index, systolic
blood pressure, and antihypertensive medication use.
These potential confounders were chosen based on
their association with incident ASCVD in previous
studies and also in our univariate analysis.
2. Do the additional risk markers improve discrimination
over and beyond the calibrated PCEs? The PCE was
known to overestimate risk in MESA (9). Thus, to
avoid overstating the contribution of the additional
risk factors in improving the PCE risk estimates, the
PCE was recalibrated to the MESA data. Calibration
was accomplished by including the PCE in a Cox
model predicting ASCVD events (10); this approach
created a calibrated pooled cohort equation (cPCE),
which used the baseline survival estimate from the
MESA data and thus reduced the risk overestimation
presented in the original PCE/score. These cPCEs
were used in all subsequent analyses. Ten-year cPCE
was calculated for each participant, including sub-
jects with type 2 DM. The cPCE included race-speciﬁc
risk estimates for black and white subjects only; risk
estimates for Hispanic and Chinese participants were
calculated by using the cPCE for white subjects, as
suggested in the new guidelines.
Discrimination was assessed by using Harrell’s
C statistic for the cPCE with and without each
additional risk marker (11,12). Cross-tabulation of the
cPCE with and without each additional risk marker
TABLE 1 Baseline Characteristics
<7.5% cPCE
(n ¼ 4,185)
$7.5% cPCE
(n ¼ 1,000)
Total Cohort
(N ¼ 5,185)
Age, yrs 58.2  8.6 73.6  6.6 61.2  10.3
Female 2,380 (56.9) 371 (37.1) 2,751 (53.1)
Race/ethnicity
White 1,606 (38.4) 363 (36.3) 1,969 (38)
Chinese 518 (12.4) 107 (10.7) 625 (12.1)
Black 1,117 (26.7) 285 (28.5) 1,402 (27.0)
Hispanic 944 (22.6) 245 (24.5) 1,189 (22.9)
Diabetes mellitus 236 (5.6) 270 (27.0) 506 (9.8)
Cholesterol, mg/dl
Total 196.2  35.1 197.2  37.9 196.4  35.7
LDL* 119.3  31.2 121.2  32.0 119.7  31.4
HDL 51.6  15.0 48.4  14.4 51.0  15.0
Triglycerides 126.6  75.5 142.7  125.8 129.7  87.7
BMI, kg/m2 28.2  5.6 28.0  4.9 28.2  5.4
Blood pressure, mm Hg
Systolic 121.0  18.5 145.0  21.9 125.6  21.4
Diastolic 71.3  10.1 75.1  11.0 72.1  10.4
Cigarette smoking
Never 2,177 (52.0) 447 (44.7) 2,624 (50.6)
Former 1,457 (34.8) 397 (44.7) 1,854 (35.8)
Current 551 (13.2) 156 (15.6) 707 (13.6)
Antihypertensive medication use 1,092 (26.1) 591 (59.1) 1,683 (32.5)
CAC score, agatston 0 (0–24.2) 94.5 (4.7–374.5) 0 (0–63.6)
hsCRP, mg/l 1.9 (0.8–4.3) 2.1 (1.0–4.1) 1.9 (0.8–4.3)
ABI 1.1 (1.1–1.2) 1.1 (1.0–1.2) 1.1 (1.1–1.2)
Values are mean  SD, n (%), or median (interquartile range). *Low-density lipoprotein (LDL) sample size ¼ 5,123
(due to missing values).
ABI ¼ ankle–brachial index; BMI ¼ body mass index; CAC ¼ coronary artery calcium; cPCE ¼ calibrated pooled
cohort equation; HDL ¼ high-density lipoprotein; hsCRP ¼ high-sensitivity C-reactive protein.
TABLE 2
CAC (ln þ
hsCRP (ln
Family his
ABI (per 0
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improvement (NRI). Bootstrapping was used to
calculate 95% conﬁdence intervals (CIs) (13). The NRI
analyses for events and nonevents were calculated
separately, as previously recommended. The NRI
analyses were conducted by using the 7.5% ASCVD risk
cutoff, per the ACC/AHA guidelines (2 categories).
Three categories of ASCVD risk (0% to 5%, 5% to 7.5%,ASCVD Event Hazard Associated With Additional Risk Markers
Univariable Multivariable*
HR 95% CI p Value HR 95% CI p Value
1, per 1.98 SD) 2.06 1.86–2.29 <0.001 1.58 1.40–1.79 <0.001
, per 1.17 SD) 1.23 1.10–1.37 <0.001 1.12 0.99–1.27 0.077
tory of ASCVD 1.57 1.26–1.95 <0.001 1.37 1.09–1.71 0.007
.11 SD) 0.69 0.63–0.75 <0.001 0.87 0.79–0.94 0.001
ation ¼ 5,185; number of events ¼ 320. *Multivariable Cox model adjusted for age,
hnicity, diabetes mellitus, total cholesterol, HDL cholesterol, BMI, systolic blood
garette smoking status, and antihypertensive medication use.
atherosclerotic cardiovascular disease; CI ¼ conﬁdence interval; HR ¼ hazard ratio;
l logarithm; SD ¼ standard deviation; other abbreviations as in Table 1.and >7.5%) were also used as a sensitivity analysis.
The improvement in Harrell’s C statistics and NRI of
the additional risk markers were directly compared. In
a subsequent analysis, the Framingham risk score (14)
was recalibrated as described for the PCE, and the
improvement in reclassiﬁcation afforded by the addi-
tion of these additional risk markers (CAC score, ABI,
hsCRP levels, and FH) was assessed by using Harrell’s
C statistics and anNRI analysis; incident CHDwas used
as the outcome of interest. The statistical analysis was
performed by using Stata version 12.0 (StataCorp LP,
College Station, Texas).
RESULTS
Of the 6,814 MESA participants, 1,629 (23.9%) were
either prescribed statins, had an ABI $1.4, or had
incomplete data and were therefore eliminated from
the present analysis. In terms of baseline character-
istics of the remaining 5,185 participants (Table 1), the
mean age of the participants included in this analysis
was 61.2 years; 53.1% were female; and 38% were
white, 12.1% were Chinese, 27% were black, and
22.9% were Hispanic. After a mean follow-up of 10
years, 320 (6.2%) ASCVD events occurred; 139 (43.4%)
were MIs, 132 (41.3%) were fatal or nonfatal strokes,
and 49 (15.3%) were CHD-related death.
In terms of the added value of the additional risk
markers, CAC score, ABI, and FH were each inde-
pendent predictors of incident ASCVD events in
multivariable Cox models (Table 2). Online Table 1
shows the hazard ratios and 95% CIs of the addi-
tional risk markers and the covariates in the multi-
variable Cox model. As to whether the markers
improve discrimination beyond the cPCEs, the Central
Illustration shows the comparative improvement in
area under the curve/C statistics afforded by the
addition of each of the additional risk markers to the
cPCE for predicting incident ASCVD; the CAC score
was the only additional risk marker to signiﬁcantly
improve discrimination.
Table 3 presents the NRI analysis for events and
nonevents when CAC score, hsCRP levels, FH, and
ABI were added individually to the cPCE. The addi-
tion of the CAC score to the model resulted in a larger
improvement in the classiﬁcation of risk than the
other risk markers but was limited to an improvement
in classiﬁcation for events (event NRI: 0.178; 95% CI:
0.080 to 0.256; nonevent NRI: –0.059; 95% CI: –0.075
to –0.030). ABI provided a very modest improvement
but the highest nonevent NRI (event NRI: 0.013;
95% CI: –0.034 to 0.051; nonevent NRI: 0.004; 95% CI:
–0.004 to 0.011). Using 3 ASCVD risk categories (0% to
5%, 5% to 7.5%, and >7.5%) instead of the 2 categories
CENTRAL ILLUSTRATION Utility of Risk Markers for ASCVD Assessment: Receiver-Operating Characteristic Curves
FRS  + FH (AUC = 0.74, p = 0.258)
FRS (AUC = 0.74)**
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PCE  + ABI (AUC = 0.75, p = 0.55)
PCE  + CAC (AUC = 0.76, p = 0.04)
PCE  + hsCRP (AUC = 0.74, p = 0.25)
PCE  + FH (AUC = 0.74, p = 0.98)
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c
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A
B
To assess predictive accuracy and reclassiﬁcation improvement of various risk markers for incident atherosclerotic cardiovascular disease (ASCVD), receiver-
operating characteristic curves showing the area under the curve (AUC) were calculated for (A) calibrated pooled cohort equations (cPCEs) and (B) cali-
brated Framingham risk scores (cFRS) for study participants. Of the factors assessed, the coronary artery calcium (CAC) score modestly improved the
discriminative ability of the cPCE. **Reference. ABI ¼ ankle–brachial index; FH ¼ family history; hsCRP ¼ high-sensitivity C-reactive protein.
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TABLE 3 NRI: Risk Markers Added to cPCE
cPCE Alone
Row Total NRI (95% CI)<7.5% $7.5 %
cPCE þ CAC
Event (n ¼ 320)
<7.5% 107 19 126 (39.4) 0.178 (0.080 to 0.256)
$7.5% 76 118 194 (60.6)
Column total 183 (57.2) 137 (42.8)
Nonevent (n ¼ 4,865)
<7.5% 3,506 202 3,708 (76.2) –0.059 (–0.075 to 0.030)
$7.5% 496 661 1,157 (23.8)
Column total 4,002 (82.3) 863 (17.7)
Total NRI for CAC 0.119 (0.080 to 0.256)
cPCE þ hsCRP
Event (n ¼ 320)
<7.5% 165 9 174 (54.4) 0.028 (–0.013 to 0.077)
$7.5% 18 128 146 (45.6)
Column total 183 (57.2) 137 (42.8)
Nonevent (n ¼ 4,865)
<7.5% 3,882 98 3,980 (81.8) –0.005 (–0.015 to 0.003)
$7.5% 120 765 885 (18.2)
Column total 4,002 (82.3) 863 (17.7)
Total NRI for hsCRP 0.024 (–0.015 to 0.067)
cPCE þ FH
Event (n ¼ 320)
<7.5% 153 12 175 (54.6) 0.056 (0.007 to 0.118)
$7.5% 30 125 155 (48.4)
Column total 183 (57.2) 137 (42.8)
Nonevent (n ¼ 4,865)
<7.5% 3,832 140 3,972 (81.6) –0.006 (–0.019 to 0.003)
$7.5% 170 723 893 (18.4)
Column total 4,002 (82.3) 863 (17.7)
Total NRI for FH 0.051 (0.000 to 0.109)
cPCE þ ABI
Event (n ¼ 320)
<7.5% 166 13 179 (55.9) 0.013 (–0.034 to 0.051)
$7.5% 17 124 141 (44.1)
Column total 183 (57.2) 137 (42.8)
Nonevent (n ¼ 4,865)
<7.5% 3,910 113 4,023 (82.7) 0.004 (–0.004 to 0.011)
$7.5% 92 750 842 (17.3)
Column total 4,002 (82.3) 863 (17.7)
Total NRI for ABI 0.017 (–0.031 to 0.058)
Values are n or n (%) unless otherwise indicated.
FH ¼ family history; NRI ¼ net reclassiﬁcation improvement; other abbreviations as in Tables 1 and 2.
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Table 2) for all the additional risk markers considered.
A total of 194 (3.7%) CHD events occurred. When
considering the comparative improvement in area
under the curve/C statistics afforded by adding each
of the risk markers to the calibrated Framingham
risk score for predicting incident CHD, the CAC
score was the only factor to signiﬁcantly improvediscrimination (Central Illustration). Table 4 displays
the NRI analysis for events and nonevents when CAC
score, hsCRP levels, FH, and ABI were added indi-
vidually to the calibrated Framingham risk score. The
addition of the CAC score resulted in a larger
improvement in the classiﬁcation of risk than the
other additional risk markers but was limited to an
improvement in classiﬁcation of events.
TABLE 4 NRI: Risk Markers Added to cFRS
cFRS Alone
Row Total NRI (95% CI)<10% 10%–20% >20%
cFRS þ CAC
Event (n ¼ 194)
<10% 132 5 0 137 (70.6) 0.119 (0.045 to 0.239)
10%–20% 26 18 2 46 (23.7)
>20% 0 4 7 11 (5.7)
Column total 158 (81.4) 27 (13.9) 9 (4.6)
Nonevent (n ¼ 4,991)
<10% 4,540 63 8 4,611 (92.4) –0.034 (–0.053 to 0.017)
10%–20% 230 101 11 342 (6.9)
>20% 3 20 15 38 (0.8)
Column total 4,773 (95.6) 184 (3.7) 34 (0.7)
Total NRI for CAC 0.084 (0.024 to 0.196)
cFRS þ hsCRP
Event (n ¼ 194)
<10% 158 1 0 159 (82.0) 0.005 (–0.027 to 0.027)
10%–20% 1 24 1 26 (13.4)
>20% 0 2 7 9 (4.6)
Column total 159 (82.0) 27 (13.9) 8 (4.1)
Nonevent (n ¼ 4,991)
<10% 4,749 16 0 4765 (95.5) –0.002 (–0.007 to 0.001)
10%–20% 28 158 6 192 (3.8)
>20% 0 3 31 34 (0.7)
Column total 4,777 (95.7) 177 (3.5) 37 (0.7)
Total NRI for hsCRP 0.003 (–0.028 to 0.026)
cFRS þ FH
Event (n ¼ 194)
<10% 150 6 0 156 (80.4) 0.010 (–0.032 to 0.074)
10%–20% 8 19 3 30 (15.5)
>20% 0 3 5 8 (4.1)
Column total 158 (81.4) 28 (14.4) 8 (4.1)
Nonevent (n ¼ 4,991)
<10% 4,681 65 0 4,746 (95.1) –0.007 (–0.013 to 0.002)
10%–20% 95 98 13 206 (4.1)
>20% 0 17 22 39 (0.8)
Column total 4,776 (95.7) 180 (3.6) 35 (0.7)
Total NRI for FH 0.003 (–0.034 to 0.069)
cFRS þ ABI
Event (n ¼ 194)
<10% 152 4 0 156 (80.4) 0.041 (–0.010 to 0.108)
10%–20% 6 17 1 24 (12.4)
>20% 1 6 7 14 (7.2)
Column total 159 (82.0) 27 (13.9) 8 (4.1)
Nonevent (n ¼ 4,991)
<10% 4,724 50 0 4,774 (95.7) –0.003 (–0.008 to 0.004)
10%–20% 51 106 12 169 (3.4)
>20% 6 18 24 48 (1.0)
Column total 4,781 (95.8) 174 (3.5) 36 (0.7)
Total NRI for ABI 0.039 (–0.011 to 0.109)
Values are n or n (%) unless otherwise indicated. Calibrated Framingham risk score (cFRS) for coronary heart disease events, which include myocardial infarction and coronary
heart disease–related death.
Abbreviations as in Tables 1 to 3.
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The goal of the present study was to assess the
improvement in discrimination that would be gained
by adding the recommended nontraditional risk
markers to the 2013 cPCE. The present study found
that among the 4 ACC/AHA–recommended nontradi-
tional risk markers studied, the CAC score provides
the highest (albeit, modest) improvement in
discrimination over and beyond the cPCE (Central
Illustration). The superiority of the CAC score seems
to be consistent across all possible ASCVD strata. To
our knowledge, this study is the ﬁrst to assess
whether nontraditional risk markers improve risk
prediction afforded by the cPCE.
Previous studies showed that CAC score, ABI,
hsCRP levels, and FH improve discrimination and
classiﬁcation of risk over the Framingham risk score
but to varying degrees (15–18). Our group (19), as well
as a report by the Rotterdam study (15), showed that
among these 4 risk markers, CAC score provided the
greatest improvement in discrimination across the
whole CHD risk spectrum and also in those classiﬁed
as intermediate risk according to the Framingham risk
score. In the 2013 ACC/AHA guidelines (1), the pri-
mary outcome was expanded to ASCVD, which in-
cludes fatal and nonfatal stroke in addition to fatal
and nonfatal MI. The PCE also includes variables for
the presence or absence of DM and race (white or
African American). The present study found that
among the 4 recommended nontraditional risk
markers, CAC score is superior for improving ASCVD
risk prediction and may be useful in individuals in
whom quantitative ASCVD risk-based treatment
decision making may be uncertain.
The magnitude of improvement in discrimination
afforded by the 4 nontraditional risk markers
beyond the cPCE seems modest compared with what
was reported in MESA using Framingham risk fac-
tors as the baseline model (16) but similar when the
Framingham risk score was used (Table 4). For
example, in the study by Polonsky et al. (16) in
which the Framingham risk factors were used as the
baseline model, CAC score had an event NRI of 0.23
and a nonevent NRI of 0.02 for incident CHD events.
In the present study, when the calibrated Framing-
ham risk score was used in the same cohort for
incident CHD events, the CAC score had an event
NRI of 0.119 and a nonevent NRI of –0.034. How-
ever, CAC scores, as well as some of the other risk
markers, produced signiﬁcant improvement in clas-
siﬁcation when the analysis was limited to those
labeled as intermediate risk according to the Fra-
mingham risk score (19).It should be noted that during the National
Cholesterol Education Program/Adult Treatment
Panel III era, these additional risk markers were only
recommended for improvement in risk assessment in
subjects with intermediate risk according to the Fra-
mingham risk score (20). Currently, these additional
risk markers are recommended for improvement in
ASCVD risk assessment in those who are not in 1 of
the 4 statin-beneﬁt groups and for whom the decision
to initiate statin treatment is uncertain (2). It is
plausible that despite the modest improvement in
discrimination observed in the present study, these
additional risk markers may still play signiﬁcant roles
for ASCVD risk assessment in a subgroup of the pop-
ulation. Studies on the improvement in discrimina-
tion afforded by these additional risk markers in
subgroups of asymptomatic individuals (primary
prevention) is needed, especially those for whom
statin therapy is not recommended by the new ACC/
AHA cholesterol guidelines (1).
Despite the ﬁnding of superior (albeit modest)
discrimination when the CAC score was added to the
PCE, its ultimate use in the clinical setting for risk
assessment (especially after the introduction of the
ASCVD risk estimator) demands consideration of
additional variables such as cost-effectiveness, radi-
ation exposure, and patient preference.
STUDY LIMITATIONS. Although participants who
were taking statins during the baseline MESA exam-
ination were excluded from this analysis, some of the
participants we did include were prescribed statins
during follow-up. This approach may have affected
our event rates and therefore our results. However,
the sensitivity analysis, in which statin use during
10-year follow-up was accounted for in our models,
did not signiﬁcantly change either our point esti-
mates or our conclusions. The MESA cohort is also not
representative of the U.S. population. In addition, the
calibrated versions of the PCE and the Framingham
risk score are not currently available to clinicians.
Therefore, although these tools are the most appro-
priate for statistical analysis, some caution may be
needed when directly applying these results to clin-
ical practice with the present PCE and Framingham
risk score.
CONCLUSIONS
In this study of well-characterized individuals
(including those who are nonwhite as well as white,
who were followed up for 10 years), CAC score, ABI,
and FH were each independently associated with
incident ASCVD beyond traditional risk factors. The
nontraditional risk factors resulted in varying degrees
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The nontradi-
tional risk markers cited by the 2013 ACC/AHA cholesterol
guidelines for ASCVD risk reﬁnement and considered in
this study provided modest degrees of improvement in
discrimination over and beyond the cPCE, including no
improvement.
TRANSLATIONAL OUTLOOK: Conﬁrmation of our ﬁndings
in other cohorts should consider the utility and the cost-
effectiveness of using these risk markers for improving ASCVD
risk assessment. The promise seen with the CAC score requires
further study.
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147of improvement in discrimination and reclassiﬁcation
of risk, including no improvement. Veriﬁcation of our
ﬁndings in other racial and ethnic groups, as well as
in other patient cohorts, is needed.
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